GW Pharmaceuticals (GWPH) Sativex, The World"s First Plant-Derived Cannabinoid Prescription Drug
GW Pharmaceuticals plc (GWPH) commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world.
GWPH has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GWPH's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type-2 diabetes, and schizophrenia.
GWPH reported the closing of the previously announced offering on the NASDAQ Global Market by the company and certain of its selling shareholders of 1,700,000 American Depositary Shares (ADSs) and the full exercise by the underwriters of their option to purchase 255,000 additional ADSs from GWPH at a price of $86.83 per ADS.
The ADSs sold in the offering consisted of 1,455,000 ADSs sold by GWPH, and 500,000 ADSs sold by the selling shareholders, and raised gross proceeds to GWPH of $126.3 million (before deducting underwriting discount, commissions and offering expenses). GWPH did not receive any proceeds from the sale of ADSs by the selling shareholders in this offering.
GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network (CRWE-PR), a social networking service which business model is based on selling advertising to businesses targeting both locally and nationally.
The CRWE Network, based on the momentum the industry has taken in positioning itself for additional grow in the future, is in the process of building an online medical marijuana informational and directory search platform (Medical Marijuana CRWE-PR http://www.medicalmarijuana.crwe-pr.com ). The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.
The CRWE-PR Finance and the CRWE Press Release ( http://www.crwepressrelease.com ) websites allow Crown Equity Holdings the instant distribution of information to the entire CRWE Network, which has reached the 719th community website in the U.S., associated with 2292 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida, Hattiesburg in Mississippi and 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
**
CRWE-PR Finance http://finance.crwe-pr.com/2014/06/26/gw-pharmaceuticals-gwph-sativex-the-worlds-first-plant-derived-cannabinoid-prescription-drug/
Read Full Disclaimer at http://www.finance.crwe-pr.com/disclaimer
GWPH has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GWPH's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type-2 diabetes, and schizophrenia.
GWPH reported the closing of the previously announced offering on the NASDAQ Global Market by the company and certain of its selling shareholders of 1,700,000 American Depositary Shares (ADSs) and the full exercise by the underwriters of their option to purchase 255,000 additional ADSs from GWPH at a price of $86.83 per ADS.
The ADSs sold in the offering consisted of 1,455,000 ADSs sold by GWPH, and 500,000 ADSs sold by the selling shareholders, and raised gross proceeds to GWPH of $126.3 million (before deducting underwriting discount, commissions and offering expenses). GWPH did not receive any proceeds from the sale of ADSs by the selling shareholders in this offering.
GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network (CRWE-PR), a social networking service which business model is based on selling advertising to businesses targeting both locally and nationally.
The CRWE Network, based on the momentum the industry has taken in positioning itself for additional grow in the future, is in the process of building an online medical marijuana informational and directory search platform (Medical Marijuana CRWE-PR http://www.medicalmarijuana.crwe-pr.com ). The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.
The CRWE-PR Finance and the CRWE Press Release ( http://www.crwepressrelease.com ) websites allow Crown Equity Holdings the instant distribution of information to the entire CRWE Network, which has reached the 719th community website in the U.S., associated with 2292 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida, Hattiesburg in Mississippi and 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
**
CRWE-PR Finance http://finance.crwe-pr.com/2014/06/26/gw-pharmaceuticals-gwph-sativex-the-worlds-first-plant-derived-cannabinoid-prescription-drug/
Read Full Disclaimer at http://www.finance.crwe-pr.com/disclaimer